PT91191B - Processo para a lactonizacao de acidos mevinicos e seus analogos - Google Patents
Processo para a lactonizacao de acidos mevinicos e seus analogos Download PDFInfo
- Publication number
- PT91191B PT91191B PT91191A PT9119189A PT91191B PT 91191 B PT91191 B PT 91191B PT 91191 A PT91191 A PT 91191A PT 9119189 A PT9119189 A PT 9119189A PT 91191 B PT91191 B PT 91191B
- Authority
- PT
- Portugal
- Prior art keywords
- process according
- compound
- alkyl
- acid
- quot
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/30—Oxygen atoms, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
- Pyrane Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Description
. ι i - : 1-:-, 1 'τ
ς:-· + t-::· "::: .. ^ .j , .£ 1 - .· :;η η: .Π t. é ti O-i ·!" Λ~ Γ ··' Ζ’ 'J. 1 Γ; Cc' 5
HOY^co2á *»
R d A é h i d~ g ::u bu 11 tu:, d o fenilo, diííí í_! -? ' 1 gru ir*
bad original \
s.né.locz-s & sono o n 1 oa ou 1001-si η uá t .1. cos condui a uma nisiuio daa-fo-;:uv lactona e ácido d 1 f. i d 1 c u i „ nõv-o.cor!' o conircidliiido nu ..ίο má c.od 1 Ocierói do alio ren diuento ouro o. 11 c cor: i c uç do do livre ou 00.I amónio foi ofectuada colo ucuoc inon ío cosòoo cuba-
1 U : - 1' 1 O. : Π .· · O O: l - 0 1 dO 10' 0 ,0 10,..: , · O_i. _ c\ ~ _ :: - - - “V õiilij, ou acetato ísluo-ddiIicg a, ou. ::ué o i mo do rafluuo, A lac f'oo ia;á j õ o o ta 1 i c a:du cola prosoroí do· ilidi. A acidioidado
bad original
·> - .- - ol! ·· · .· ao :a.::3.:; a. a a a. d;,; da ua aaid- f i lavada do prado do:· I a a : ::r· a alaora 'a invar ter o acoA I iiaaa a-ara a voa.sa a.:- ; --1:--- ri i h 1 H •iov sal e=o | ,q - 3 a; : _ _1 1 -]- . __ : — · . de • ·· . _ · a,aa a a _ loc 3 ,z ee - e e . e-~e 3 a . a. - a.v-aioa aa o:a-r a da:, lid pela '-eao :: da: a: a o d· —prado a a o da a : ; a a : -Hv, , 0.0-0 La .· □ d ãLLL.· Γ- r ea,g en t a ãã.·- ãalã d- des 11 1 .? e S’ c· a· :e: orai;;:a a. d d. ea oabogaa ao O. d Oi t G ·, A ;- aa.ddaa da do-a, a Γ· :· V V A! da aal a raio ia— a cauiinie inve i- r e C DG3 i c da do equilíbrio paea o l.adc lãctcna . Π- ·" i ’ cr: -ãdCd e c a Lrdariaraa ,a Ξ C' ' r.Ã ffi - -½ dlã; CC ·' C "= * ã 3 ene, T i p iere ata o dada draaba de aa:.da : v. :d Όνο a·:: ee-< cecc- c c a d a 1 i. o a o a r ácid d r aaa,; a '-- p lí a n t ο ο o: j. o a d.' a. r ta f:L ··· >Λ Lee:, cp.jd de ,·- o a a ;?q d - a j.ij i ξ e e d e .a..;. ::aaa booaaa: de . · · e para i t i ndo a foríiícd· aaaoãõ.ida da aub—a ada- actana e x. __ ·_ ;.J z> * Sob a a d do d i. ç das da rsa.Cidlu, α produto 3 -hidra-a i 1 e - íad ado durão te oericdc'5 do tesnpc· pre 1 r-ngade-s ao á o id o qae r d o d u d a d u a a t i d a ci e s crasLanteã da dioarc i. ' o qu.a ds l: :v, raacc?: de ea t er i f i a ac ao entra o graoe 3-hidro/i 1c da 3-da. d raa i. acdona e o á ai do Iivre„ r—- -— -------
$AD ORlGfNAL
Uma segunda impureza, t-enul tente d a desidra taç^o do grupo 3-hidrc;; i. I α no anel lactanj , fce também ciu-sr· ado Líand:; condicSes de I actoni zaçao ar. ter i ores» Eso? impureza foi do τι esmo modosa inef i.c ien ieoen te removida poso reooòsta! loaoSo, originardí: menores rendi men tos. 0 preser, te invento alivia esto problema..
BAD ORIGINAL
o» -a ca. ar ti τ ca caio :\a rca ;< n a: η d a ο o ç3c completa da 1 aciona r lacto ri a. a conduz aos lo è. czncletíÇno da rir-n:z:-ac, a lactona a cor tinuansir do· rsm loco que se forma, minimizando a &;;dcci riu. da raa.op ΐο a min imoz ar zio aooim reaccao coaierior dscs formar dmmeroo., 1 : -· - Z O p ?- ' .· . lado d nizaçao, No prezar; i ;;io naco os reaceu a 1 a c. teria ·· c C Ο Γ: d .1. -~ z c a 1 para a ou obLeíncis um C ;·: ΊΗ r jroci e Ti 3. S 1 Tí " L: Γ ' v; de lactonizai *ee ccíTt- .
BAD ORíGINAL \
As ''antaçens principais realizadas no o o iovonto con.oarodai com a arte anterior saio prosLitivids.de do orocesoo e pi.rsaã do produto ai .nsr :aiaaOs processos ar. ter'i o-,es da. arde sã.::: conduzidos num meie a 1 lamente diluído (0,1 M > a rim de n:in imi zar a TCrTaião do diíiisro. 0 presente irvsnto ps-mita a 1 acton.icação a conceri traçSes muito maiores C" õ,24r1> iselhorando assim • " *
BAD ORfG/WAL
!' aon t U ΐ. ÉiT; ífi-?r i^r- prsccsa ano a " ; c:: sdicicn ; i os ; . ·.·. :: :h:;!v5:v:í o concentrado antes de isolar a iactona; no aressrris prccai:·; a novo o cresen c& processo dssonstra urna ssaor sfl.cisrO ia a:? çuo a a-'da andarcor,
Er --“o laçado à pu.r32í do produto, o no toco da ar" te a” te!·'· j.oi" crq inoc ua 300:. — produto c qual co-n a a cia. r , >* a. a ,1. oregíduã no o Γ', n t a; o r
O II
CR urn.:;> iopurscs dioén d i f i c i 1 do rorevor, enquanto que L, ic L V 0' i 5 desta irpuracã SCO as co ndiçofic do láctr-oaíc u a :Od,r sã'- roeu o idos ir ί"?ΠΟ“· GC Qi.l·? d* , "'u * ft é alquilo:
R( d l-ò, CR-, Oh , CH^DCf^QlK^, iCCUR,, C(-0uR,K 0 H ou MH , At u u:n cati.Sc ostàli
BAD ORIGINAL
Κ — S Γ· a.'U L, _ .... ; a ;
•ί -- R. Ο F\_ S:ÍC 1 Π C ίΐ DOS'· C ΡΟ Ο Ο ;τ'; ÍL· Γ'[ 00/ 0 Η -U : . . elcui Is.
.oss;. en âquá, □ sol -senta particular á- e t er.-;u.- a :!u peias csracis--'.arisco:.: ce uúslíI :rccêcc . : . a c fêcsrcí cs o c 1 u b .i. I idade entre o scicio r sss ’ hsdrcai c a leciona.-, a c ' i s t a 1 i :: aça· s selêctccc. a soinéij.caa da. ccistslizsceo, m? íusc^c sql: j-eclvente orgânico. acetona e cetenol de preferencis ácido s ·; ? ....;, a.c o ton i t r i 1 o ou. s : i l) j Ácccp-r; :co ou. orq sn Lco cio sc i d 1 c d s d a suf iciente : ·· · · · c a : 3.1 i. z a a f.ornaçáio de una 1 ac tens. * ã;sr:plos ca êcidcs apropri.;·--.ias que poder ser sepcscsdcc ato ácido fero.ico, fccdcaicc , t r i f 1 u oro a c ético, su 1 f á r:. ca, c 1 o r i d r i c o , per c i. 6 r i c a , p -1 o 1 u s' “ ca - aLcitesuiaca e aecancsul fónica. A lactanizaçuc coda ser efaotuada ac longo de caca
ssoparâtaras d e 2 ã ° Γ a 30°C , do ort^erEncia, ·—. __·—. ror stico que a tas peradLUsa π3o suba a c .. τ r. :j>~ 30 °C Ί3 ve to crigirier is a for !T! a ·;; 0 O 0 cêêcSãse dõ Ã: L· b~D:"OdU. tO T □ o c ati.de e metálicos preferidos são catides de c"; etãiS c:a 1 inos· , ta 1 como sódio ou potássio, catives de metais a1 c a 1 i η o rrosos, tal CO;T;Q cálcio ou magnésio, ou catides de o u t r o s ga-ru.
bad original
-roais cal como: slu i r= :i, , i i ' : -rc,,sl c.j ocdelcc, Ge os iodes ae τs 00 1 ·· 1 oíl: η0 c 0- ti Rss .- rosal alcalino terroso, 0 ceco.Giês de clocvriO o:.ár p -e -Ge ri,:;-,·::.. 000: orsoaics de sódio, cálcio e e 1:.:::,:. rio se '.O Ode sT: - ; c pref cr. : - i r-\ cc
U; i i -?. i.r ;: ir· O U á O
3 de iór'medis (I - 1 - 1 d R. é CH... : J. U '
U ; :..i .4. '4 ou i , 1 111r ocj.11 o e RR 0 lH_ . s e mH s e 1· .· ·' au.ni .L ' ·*!·' solvente orpanico é doido acético, acedem: i. cri 1 o :oísÍi:ad::r ácido o ácido t d f 1 uor ::s : e d 1 fónico. Nu. m a subcle.ose R é 1 ,, 1 — d ime r í 1 cr
0.· o u á c i d o o e t a r. os··.. 1 — pilo, ·:: sol ver, te ocga-do á á ::0:0o trodooiro-
c processe do oresente o lo.το.dando: o invento
Go E:;sito1 os seoLcntea ilustram inverta s não devoo ser considerados 00 aureserdado nas Reivi.nd icacoes em enexo.
η n a f t. i 3. - 1
i
A a 3. torna DcrcS:: da água· (32 mi) foi a::::::"ací cia rente o ;;ar:rdu de 1 hora. A 00000-0 foi a ssgoo::- agitada i.aorta .0:1 2 horas, ϋ ácido t r 1 f 3. ucoocét: 1. c o foi noa ora 1 iza. d o· 001 h.i .d oi 1 ifj do ο-πο corronfrajo ' 5 :i 3 oi , 1,3o 5 ))n,; 7v rrc 3 ; o quãi foi adio sonado 1 en .taõõn -L. „ 00 arrefecoãsnt _ .!_ . - -· -'! -1 G c: o r; j a n t 0 f 0 i a seca .1 Γ " π ítj.gd c a r a p te 1 HG r 0 e r. S ca: a i. r 0 Z da. to f 0 3. d :-ajj a 1 ·? V a - 'ZZrJi |pp r, 1 . = õ-o 7; 1 s t a _£ ο 0 d 0 E-.zé t. icc-á g a a ( 1:2 v / ) sedaida por lava geo CC :T: 100 0 I da . A P ,r\ ρ ,-Ã 7 1 0 t f i ξ o ::eso conetant ILO i p· v soro .d. — — - UÍ7! imento s L‘ r< v e d 0 •r> Z C) 10 para cfrerccs 0 c on.G =:::· etc Za7 ti t a 3. ρ: C Ci IT! ..ira páreos do hSfy‘í (HPLio, o novel de dinera foi ""“•'WWf bad original \
d Ι .· ,3,6- la tj- h Ldra- Α - E 1 , 3,3 , 7,3 -, 2a ". :-- ; -Hí 3,i d r 3 (b , ò to) — d ~t. < b '> - 2 — d i oat:11 to t i ' i I a - 1 ) — i ; 9 )—o a d d 11 ]-72 7 ; 22'7 " -1 _.-o. d i.:.- i.ro - iTr-no 1 : , o 327 - hi-d··':. : r,J :,'h :;l3 3í:i-;: 2" , 7~"2- -: da:. ao.: apon - .-.vis. nustsra to ipipp. a c á t i. -r o 24 7'· olf , ;-:uj (2-:; 1 ' a 22-23 °2' ,0:1, -3.3
f;c , J õ.
Aijbp 'çr: rH; -~ - -r-o 3.S , - ; ; i } * 1 : 3,d i C 1ΟΓ, P d 3 . -l ·- bo ido dO 110-.:.:1 1 Γ ΞΡ 1 . . i .. -3 0 23... , :,-o "-Pd 0 *í - ' 3 i. -? -J10 loiõ-i-:; : · - Õ- 11V -; ‘ 7 '7 "1111.1 r ". da 00:.1:..0-.1 ,J : *: , Q ccnjun ::o "oi a. aa 3i :' a 0 1 d no io -' o 0 t 0 d hc-fr. e ;> - f-- ... 1 —' r-· "1 1 tra-dõ a I - "-oda lio -- -Po - 1 p‘;o . 7 7 ΓΠ7 13.t ....... .· „ !-1 : :.·. ido apatia õ-ap,1 (1:2 v / v > aadi i : 1 :õ- la vagem com 10ã o 1 -3 - Ãqu.a - A papo f 7 · J õ. ;*· 0 7. ·.?. a p-aao ::00 a tan da in '.'aooQ ·?. 33 °2 0 0 b u íT: v.?.rr.i.!T:9fi tO :z'J.S ,·' a da a 07 ; " -3. c bierooo ti t_ i G C G:Tí _·.(!: 3. ptp ;-e 7; a da ? — » / ; Hcd_c ; , 3 n,vei -d 0 dioaio foi
Bad origiNal
Ρrξ ρ:? r agâo de -:-:)-:2-:3(3)-:2,2-;?;€· t i 1 tat i r i 1 c:< i ) -2 ) 3 ) , i 1 R ) -2 imeti I -1,2,6,7,2 a 1 R ) — he >;ahid ron a f ti 1 — 1 í S ) j a ti 1 ’ - 4 < R ) ~r i d ro;: i--3,4,5,ò-tet^ah.id γο-2Η- p i ran-2-on a U ooopost
yUlH J J _! p t O
d D rn titula έ prspi" ma s sufa stituinde 7 — C1,2 't _o 3 ) - \ 2,2-di;net i 1 :IÍ '· ‘ "j r" X an C -5. t. O da amònio c CíTíO 8. - a;n õ Γ; t 8 acetona ou a o a t o ni cl vente orgânico, mas c ai 1. 2. w. -i L.r n a ρ r e s s r: ~ a de u:.i , / , h , H;i i R> -Meus -;: i 5 — 1 13)—na- til) — ubstsncis. a ser trilo podem e e r om um sol-. -en te a sssda da pH a
Exemplo 1 cu Enemplc 2 h i d r a-2 1S5 ,3 Fu -di met i. 1 3 í R ) , ã ( R )-d i hid rc a i hcct lac ionizada - AI terce, i iv substituídas ccmc c s neutra,, o ácida à nsutr pH 6, BAD ORIG'Mλι
Claims (2)
- ο ιιBAD ORIGINAL t r .¾ ·;; 0/" 0 r\ d ; d 0 ·' I • / 1 1 0 ? £ O tr-L< t 0? r?0H :. ·: iΓ: rod·.. t: j 1 r.ctona ; ι I ; ;(II) a.'.--: » --- · -- £ £ .£ £ .r. o - ;·- £ £ ~ 0 ' a ::'s o 0 0 0 * . - ~ — L. .. - por 1 ^ or- c:V o· : s sr rd- * : i . ; -T.?. . - Pr nassa de scaado :: c,i: a. ÍF ei vis dias £ 3. 0 J ; ι- λ·:: - ré irado pc-·· R sor' esc boi t i 1 c cl· - i i-dicsti1prop i 1 0e b — 5Pi duplas í :;.g a a des » 4b , -- Processo ds acordo C C s Reivindica t -**í 1 .Ι Car0C~ hír uuado por o ssl to PRà-Pí S 0: 1 OCO i. ? d Ο e n t =* 0 id0 0 C 0 ρic o , acet oni ά'ΐ’ο ou dcetoí. * rr; • Fr·"ar:osso ds acordo C ΟπΊ a Rei.vindaca çS o 4:. 0. 3. 0 0 0 Γ. 0 0 irado por o ca to.I isador «eido s 3 r ·_·. s 1 scc lonodo Ç?Π X. 0 0 * á.C ldu17 fórmico, fosfórico, trifluoroacético, sulfúrico, clorídrico, perclórico, p-toluenossulfónico e metanossulfónico.
- 64. - Processo de acordo com a Reivindicação 5, carac-terizado por R ser 1,1-dimetilpropilo. 7a. - Processo de acordo com a Reivindicação 6, carac-terizado por o solvente orgânico ser ácido acético e Z ser NH4+. 8a. - Processo de acordo com a Reivindicação 7, carac-terizado por o catalisador ácido ser ácido trifluoroacético, ou ácido metanossulfónico. 9a. - Processo de acordo com a Reivindicação 8, carácter izado por o catalisador ácido ser ácido metanossulfónico. 10a. - Processo de acordo com a Reivindicação 5, caracterizado por R ser sec-butilo. 11a. - Processo para a preparação de um composto de estrutura (II):em que (II) R é 01-10 alquilo r1 é ch3, ch2oh, ch2oc(=o)r2, co2r3, C(=0)NR4R5, OH, CH2OR2 ou CH2NR4R5; Z é H ou NH.+ ou um catião metálico; 4 R2 é C alquilo; R3 é H ou alquilo; R4 e R5 são independentemente seleccionados entre H ou alquilo; a e b são ambos ligações duplas ou um de a e b é uma ligação simples; caracterizado por compreender o tratamento de um composto de estrutura (I) 0em que R, R^, a e b são definidos em relação à estrutura (II) e em que Zé H, NH4+ ou um catião metálico num solvente orgânico miscível com a água, com um catalisador de ácido forte e por, em seguida, se adicionar gradualmente água até se efectuar a cristalização da lactona a partir do meio de reacção, mediante o que se produz o composto de estrutura (II) contendo menos de 0,2% de impureza dimérica. 12a. - Processo de acordo com a reivindicação 11, caracterizado por R ser C ^ alquilo, R^ ser CH3 e Z ser H ou ΝΗλ + . 4 13a. - Processo de acordo com a reivindicação 11, caracterizado por o solvente ser ácido acético, acetonitrilo ou acetona. 14a. - Processo de acordo com qualquer uma das reivindicações 11 a 13, caracterizado por Z ser NH4+. 15a. - Processo de acordo com qualquer uma das reivindicações 11 a 14, caracterizado por o catalisador de ácido forte ser ácido fórmico, fosfórico, trifluoroacético, sulfúrico, clorídrico, perclórico, p-toluenossulfónico ou metanossulfónico. 16a. - Processo de acordo com a reivindicação 11, caracterizado por se obter um composto em que R^ é CH^. 17a. - Processo de acordo com a reivindicação 11, caracterizado por se obter um composto em que R.^ é OH. 18a. - Processo de acordo com qualquer uma das reivindicações 11, 16 e 17, caracterizado por se obter um composto em que R é sec-butilo ou 1,1-dimetilpropilo e a e b serem ligações duplas. 19a. - Processo de acordo com a reivindicação 11, caracterizado por se obter a 6(R)-[2-[8(S)-2,2-dimetilbutinilo-xi)-2(S),6(R)-dimetil-1,2,6,7,8,8a(R)-hexa-hidronaftil-1(S)]- 20 etil]-4(R)-hidroxi-3,4,5,6-tetra-hidro-2H-piran-2-ona contendo menos de 0,2% de impureza dimérica. 21a. - Processo de acordo com a reivindicação 11, caracterizado por se obter a 6(R)-[2-[8(S)-(S-metilbutiriloxi)--2(S),6(R)-dimetil-1,2,6,7,8,8a(R)-hexa-hidronafti1-1(S)]etil]--4(R)-hidroxi-3,4,5,6-tetra-hidro-2H-piran-2-ona contendo menos de 0,2% de impureza dimérica. Lisboa, 17 de Julho de 1989J. PEREIRA DA CRUZ Agente Oficial da Propriedade Industrial RUA VtCTOR CORDON. 10 A 3.“ 1200 USBOA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/221,475 US4916239A (en) | 1988-07-19 | 1988-07-19 | Process for the lactonization of mevinic acids and analogs thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PT91191A PT91191A (pt) | 1990-02-08 |
| PT91191B true PT91191B (pt) | 1995-03-01 |
Family
ID=22827965
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT91191A PT91191B (pt) | 1988-07-19 | 1989-07-17 | Processo para a lactonizacao de acidos mevinicos e seus analogos |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US4916239A (pt) |
| EP (1) | EP0351918B1 (pt) |
| JP (3) | JPH0273078A (pt) |
| KR (1) | KR970011286B1 (pt) |
| CN (1) | CN1022831C (pt) |
| AT (1) | ATE111459T1 (pt) |
| AU (1) | AU609319B2 (pt) |
| CA (1) | CA1287639C (pt) |
| CS (1) | CS274640B2 (pt) |
| CY (1) | CY1813A (pt) |
| DE (1) | DE68918191C5 (pt) |
| DK (1) | DK173115B1 (pt) |
| ES (1) | ES2058475T3 (pt) |
| FI (1) | FI92695C (pt) |
| HK (1) | HK136894A (pt) |
| HR (1) | HRP930685B2 (pt) |
| HU (2) | HU202511B (pt) |
| IE (1) | IE64304B1 (pt) |
| IL (1) | IL90925A (pt) |
| LV (1) | LV11033B (pt) |
| NO (1) | NO172800C (pt) |
| NZ (1) | NZ229879A (pt) |
| PT (1) | PT91191B (pt) |
| SI (1) | SI8911362A (pt) |
| YU (1) | YU47492B (pt) |
| ZA (1) | ZA895458B (pt) |
Families Citing this family (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4916239A (en) * | 1988-07-19 | 1990-04-10 | Merck & Co., Inc. | Process for the lactonization of mevinic acids and analogs thereof |
| GB9007738D0 (en) * | 1990-04-05 | 1990-06-06 | British Bio Technology | Compounds |
| US5223415A (en) * | 1990-10-15 | 1993-06-29 | Merck & Co., Inc. | Biosynthetic production of 7-[1',2',6',7',8',8a'(R)-hexahydro-2'(S),6'(R)-dimethyl-8'(S)-hydroxy-1'(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoic acid (triol acid) |
| US5250435A (en) * | 1991-06-04 | 1993-10-05 | Merck & Co., Inc. | Mutant strains of Aspergillus terreus for producing 7-[1,2,6,7,8,8a(R)-hexa-hydro-2(S),6(R)-dimethyl-8(S)-hydroxy-1(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoic acid (triol acid),I) |
| AU660132B2 (en) * | 1992-12-21 | 1995-06-08 | Bayer Aktiengesellschaft | Substituted 4-phenyl-pyridones and 4-phenyl-2-alkoxypyridine |
| ES2133158T3 (es) * | 1993-01-19 | 1999-09-01 | Warner Lambert Co | Formulacion ci-981 oral, estable y proceso de preparacion del mismo. |
| IN186880B (pt) * | 1997-10-28 | 2001-12-01 | Ranbaxy Lab Ltd | |
| IN186879B (pt) * | 1997-10-28 | 2001-12-01 | Ranbaxy Lab Ltd | |
| ZA9810764B (en) * | 1998-04-22 | 1999-08-13 | Ranbaxy Lab Ltd | An improved process of lactonization in the preparation of statins. |
| CA2240983A1 (en) | 1998-06-18 | 1999-12-18 | Yong Tao | Process to manufacture simvastatin and intermediates |
| WO2000034264A1 (en) * | 1998-12-10 | 2000-06-15 | Kaneka Corporation | Process for producing simvastatin |
| SK282679B6 (sk) * | 1999-04-16 | 2002-11-06 | Biotika, A. S. | Spôsob izolácie lovastatínu z vyfermentovanej pôdy |
| EP1110959A4 (en) * | 1999-06-29 | 2001-12-05 | Kaneka Corp | METHOD FOR SELECTIVE LACTONIZATION |
| US6380401B1 (en) | 1999-10-27 | 2002-04-30 | Merck & Co., Inc. | Lactonization process |
| AU4183301A (en) | 2000-03-03 | 2001-09-17 | Biogal Gyogyszergyar | A process for purifying lovastatin and simvastatin with reduced levels of dimeric impurities |
| NL1017548C2 (nl) * | 2001-03-09 | 2002-09-10 | Synthon Bv | Een lactonisatie proces. |
| US6797831B2 (en) * | 2001-05-18 | 2004-09-28 | Aurobindo Pharma Limited | Process for lactonization to produce simvastatin |
| KR100407758B1 (ko) | 2001-08-27 | 2003-12-01 | 씨제이 주식회사 | 스타틴의 제조에 있어서 락톤화 방법 |
| KR100502834B1 (ko) * | 2002-03-25 | 2005-07-20 | 보령제약 주식회사 | 개선된 락톤화 반응에 의한 심바스타틴의 제조방법 및이의 정제방법 |
| EP1496982A4 (en) * | 2002-04-16 | 2006-07-19 | Merck & Co Inc | SOLID FORMS OF SALTS WITH TYROSINE KINASE EFFECT |
| AR040588A1 (es) | 2002-07-26 | 2005-04-13 | Schering Corp | Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa |
| US20040132771A1 (en) * | 2002-12-20 | 2004-07-08 | Pfizer Inc | Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors |
| AU2003283769A1 (en) | 2002-12-20 | 2004-07-14 | Pfizer Products Inc. | Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor |
| KR20050098313A (ko) | 2003-02-11 | 2005-10-11 | 플러스 케미칼스 비.브이. | 제어된 범위의 심바스타틴 이량체 함량을 갖는심바스타틴의 제조 방법 |
| CN1839114A (zh) | 2003-08-21 | 2006-09-27 | 默克弗罗斯特加拿大有限公司 | 组织蛋白酶半胱氨酸蛋白酶抑制剂 |
| EP2428516A1 (en) | 2003-11-19 | 2012-03-14 | Metabasis Therapeutics, Inc. | Novel phosphorus-containing thyromimetics |
| EP1732912B1 (en) * | 2004-03-30 | 2008-11-12 | Lupin Ltd. | An improved method for manufacture of 4-hydroxy pyran-2-one derivatives |
| DE602004023004D1 (de) * | 2004-09-08 | 2009-10-15 | Jubilant Organosys Ltd | Verbessertes verfahren zur lactonisierung bei der herstellung von statinen |
| EP1807070A1 (en) * | 2004-09-29 | 2007-07-18 | Schering Corporation | Combinations of substituted azetidinones and cb1 antagonists |
| WO2006059346A2 (en) * | 2004-12-01 | 2006-06-08 | Morepen Laboratories Limited | An improved process for lactonization to produce highly pure statins |
| WO2006062876A2 (en) | 2004-12-09 | 2006-06-15 | Merck & Co., Inc. | Estrogen receptor modulators |
| AU2006302797B2 (en) | 2005-03-02 | 2012-02-02 | Merck Canada Inc. | Composition for inhibition of cathepsin K |
| ATE550019T1 (de) | 2005-05-17 | 2012-04-15 | Merck Sharp & Dohme | Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs |
| EP1741427A1 (en) | 2005-07-06 | 2007-01-10 | KRKA, D.D., Novo Mesto | Pharmaceutical composition comprising simvastatin and ezetimibe |
| WO2007020079A2 (en) * | 2005-08-17 | 2007-02-22 | Synthon B.V. | Orally disintegratable simvastatin tablets |
| PE20070335A1 (es) * | 2005-08-30 | 2007-04-21 | Novartis Ag | Benzimidazoles sustituidos y metodos para su preparacion |
| US20070117996A1 (en) * | 2005-11-21 | 2007-05-24 | Srinivasulu Gudipati | Process for preparing simvastatin |
| CA2634235A1 (en) * | 2005-12-21 | 2007-07-05 | Schering Corporation | Combination of an h3 antagonist/inverse agonist and an appetite suppressant |
| CA2634940A1 (en) * | 2005-12-21 | 2007-07-05 | Schering Corporation | Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and h3 receptor antagonist/inverse agonist |
| GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| KR101464385B1 (ko) | 2006-04-19 | 2014-11-21 | 노파르티스 아게 | 6-o-치환된 벤즈옥사졸 및 벤조티아졸 화합물, 및 csf-1r 신호전달의 억제 방법 |
| WO2008030382A1 (en) * | 2006-09-05 | 2008-03-13 | Schering Corporation | Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis |
| AU2007300627B2 (en) | 2006-09-22 | 2012-02-16 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
| US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
| BRPI0806245B1 (pt) | 2007-01-10 | 2022-01-25 | Msd Italia S.R.L. | Compostos de fórmula i e seus usos |
| CN101679266B (zh) | 2007-03-01 | 2015-05-06 | 诺华股份有限公司 | Pim激酶抑制剂及其应用方法 |
| AU2008254425A1 (en) | 2007-05-21 | 2008-11-27 | Novartis Ag | CSF-1R inhibitors, compositions, and methods of use |
| WO2009002495A1 (en) | 2007-06-27 | 2008-12-31 | Merck & Co., Inc. | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
| US20090048335A1 (en) * | 2007-08-17 | 2009-02-19 | Venkata Naga Mandava | Process for preparing simvastatin |
| CN101945853B (zh) | 2007-12-21 | 2014-08-20 | 配体药物公司 | 选择性雄激素受体调节剂(sarm)及其应用 |
| AU2009218573A1 (en) * | 2008-02-27 | 2009-09-03 | Thommen Medical Ag | Implant and method for the manufacture thereof |
| EP2204170A1 (en) | 2008-12-01 | 2010-07-07 | LEK Pharmaceuticals D.D. | Pharmaceutical composition comprising ezetimibe and simvastatin |
| EP2216016A1 (en) | 2009-02-06 | 2010-08-11 | LEK Pharmaceuticals d.d. | Process for the preparation of a pharmaceutical composition comprising ezetimibe |
| WO2010093601A1 (en) | 2009-02-10 | 2010-08-19 | Metabasis Therapeutics, Inc. | Novel sulfonic acid-containing thyromimetics, and methods for their use |
| EP2413932A4 (en) | 2009-04-01 | 2012-09-19 | Merck Sharp & Dohme | HAMMER OF ACT ACTIVITY |
| CA2777043C (en) | 2009-10-14 | 2015-12-15 | Schering Corporation | Substituted piperidines that increase p53 activity and the uses thereof |
| CN101704808A (zh) | 2009-11-20 | 2010-05-12 | 西南合成制药股份有限公司 | 制备他汀类化合物的内酯化方法 |
| CN104098537A (zh) * | 2009-11-20 | 2014-10-15 | 北大医药股份有限公司 | 制备他汀类化合物的内酯化方法 |
| EP2368543A1 (en) | 2010-03-25 | 2011-09-28 | KRKA, tovarna zdravil, d.d., Novo mesto | Method of preparing a granulated pharmaceutical composition comprising simvastatin and/or ezetimibe |
| EP2584903B1 (en) | 2010-06-24 | 2018-10-24 | Merck Sharp & Dohme Corp. | Novel heterocyclic compounds as erk inhibitors |
| CN103068980B (zh) | 2010-08-02 | 2017-04-05 | 瑟纳治疗公司 | 使用短干扰核酸(siNA)的RNA干扰介导的联蛋白(钙粘蛋白关联蛋白质),β1(CTNNB1)基因表达的抑制 |
| RU2745848C2 (ru) | 2010-08-17 | 2021-04-01 | Сирна Терапьютикс, Инк. | ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА B (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК) |
| US8883801B2 (en) | 2010-08-23 | 2014-11-11 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors |
| EP2613782B1 (en) | 2010-09-01 | 2016-11-02 | Merck Sharp & Dohme Corp. | Indazole derivatives useful as erk inhibitors |
| US9242981B2 (en) | 2010-09-16 | 2016-01-26 | Merck Sharp & Dohme Corp. | Fused pyrazole derivatives as novel ERK inhibitors |
| CA139852S (en) | 2010-10-15 | 2011-11-23 | Reno de Medici SpA | Christmas tree |
| WO2012058210A1 (en) | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA) |
| WO2012087772A1 (en) | 2010-12-21 | 2012-06-28 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
| EP2675440B1 (en) | 2011-02-14 | 2020-03-25 | Merck Sharp & Dohme Corp. | Cathepsin cysteine protease inhibitors |
| WO2012143879A1 (en) | 2011-04-21 | 2012-10-26 | Piramal Healthcare Limited | A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation |
| US9393224B2 (en) | 2011-08-26 | 2016-07-19 | Osaka University | Prophylactic and/or therapeutic agent for cardiovascular complications of diabetes |
| EP2770987B1 (en) | 2011-10-27 | 2018-04-04 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
| EP2597092A1 (en) | 2011-11-24 | 2013-05-29 | Sterling Biotech Limited | A process for purification of lovastatin |
| EP3919620A1 (en) | 2012-05-02 | 2021-12-08 | Sirna Therapeutics, Inc. | Short interfering nucleic acid (sina) compositions |
| CA2882950A1 (en) | 2012-09-28 | 2014-04-03 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
| SMT201700595T1 (it) | 2012-11-28 | 2018-03-08 | Merck Sharp & Dohme | Composizioni e metodi per trattare il cancro |
| WO2014100065A1 (en) | 2012-12-20 | 2014-06-26 | Merck Sharp & Dohme Corp. | Substituted imidazopyridines as hdm2 inhibitors |
| WO2014120748A1 (en) | 2013-01-30 | 2014-08-07 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as hdm2 inhibitors |
| WO2015034925A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| WO2015051479A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Cathepsin cysteine protease inhibitors |
| RU2692799C2 (ru) | 2013-10-08 | 2019-06-27 | Мерк Шарп И Доум Корп. | Ингибиторы цистеинпротеаз катепсинов |
| EP3613418A1 (en) | 2014-01-17 | 2020-02-26 | Ligand Pharmaceuticals, Inc. | Methods and compositions for modulating hormone levels |
| WO2015120580A1 (en) | 2014-02-11 | 2015-08-20 | Merck Sharp & Dohme Corp. | Cathepsin cysteine protease inhibitors |
| JO3589B1 (ar) | 2014-08-06 | 2020-07-05 | Novartis Ag | مثبطات كيناز البروتين c وطرق استخداماتها |
| US10975084B2 (en) | 2016-10-12 | 2021-04-13 | Merck Sharp & Dohme Corp. | KDM5 inhibitors |
| WO2019094312A1 (en) | 2017-11-08 | 2019-05-16 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| EP3706742B1 (en) | 2017-11-08 | 2023-03-15 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
| EP3833667B1 (en) | 2018-08-07 | 2024-03-13 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
| WO2020033285A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| WO2020033282A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| CA3108388A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| AU2020257397B2 (en) | 2019-04-19 | 2026-02-26 | Ligand Pharmaceuticals Inc. | Crystalline forms and methods of producing crystalline forms of a compound |
| EP4076459B1 (en) | 2019-12-17 | 2026-04-29 | Merck Sharp & Dohme LLC | Prmt5 inhibitors |
| ES3022307T3 (en) | 2019-12-17 | 2025-05-28 | Merck Sharp & Dohme Llc | Prmt5 inhibitors |
| EP4076460B1 (en) | 2019-12-17 | 2026-01-21 | Merck Sharp & Dohme LLC | 1,4-dihydro-2h-spiro[isoquinoline-3,4'-piperidine derivatives as prmt5 inhibitors for the treatment of cancer |
| ES3074517T3 (en) | 2019-12-17 | 2026-07-21 | Merck Sharp & Dohme Llc | 4-(3,4-dihydroisoquinolin-2(1h)-yl)-3-hydroxypiperidine derivatives as prmt5 inhibitors for the treatment of cancer and sickle cell disease |
| WO2024180169A1 (en) | 2023-03-02 | 2024-09-06 | Carcimun Biotech Gmbh | Means and methods for diagnosing cancer and/or an acute inflammatory disease |
| WO2025147589A1 (en) | 2024-01-05 | 2025-07-10 | Osanni Bio, Inc. | Implants, compositions, and methods for treating retinal diseases and disorders |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA81703B (en) * | 1980-02-04 | 1982-09-29 | Merck & Co Inc | New antihypercholesterolemic compounds,intermediates and processes |
| JPS5948418A (ja) * | 1982-09-10 | 1984-03-19 | Sankyo Co Ltd | 高血清過酸化脂質血症治療剤 |
| US4582915A (en) * | 1983-10-11 | 1986-04-15 | Merck & Co., Inc. | Process for C-methylation of 2-methylbutyrates |
| US4611068A (en) * | 1984-11-19 | 1986-09-09 | Merck Frosst Canada, Inc. | Process for the preparation of HMG-CoA reductase inhibitors and intermediate compounds employed therein |
| US4611067A (en) * | 1985-01-31 | 1986-09-09 | Merck & Co., Inc. | Process for the preparation of HMG-CoA reductase inhibitors and intermediate compounds employed therein |
| US4772626A (en) * | 1986-01-31 | 1988-09-20 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
| PT85109A (en) * | 1986-06-23 | 1987-07-01 | Merck & Co Inc | Process for the preparation of hydroxy-tetrahydropyranone derivatives or corresponding ring opened dihydroxy acids which are hmg-coa reductase inhibitors |
| US4857546A (en) * | 1988-01-07 | 1989-08-15 | Merck & Co., Inc. | Novel HMG-CoA reductase inhibitors |
| US4916239A (en) * | 1988-07-19 | 1990-04-10 | Merck & Co., Inc. | Process for the lactonization of mevinic acids and analogs thereof |
-
1988
- 1988-07-19 US US07/221,475 patent/US4916239A/en not_active Expired - Lifetime
-
1989
- 1989-07-10 YU YU136289A patent/YU47492B/sh unknown
- 1989-07-10 NZ NZ229879A patent/NZ229879A/en unknown
- 1989-07-10 SI SI8911362A patent/SI8911362A/sl not_active IP Right Cessation
- 1989-07-11 IL IL90925A patent/IL90925A/xx not_active IP Right Cessation
- 1989-07-11 FI FI893363A patent/FI92695C/fi not_active IP Right Cessation
- 1989-07-17 CS CS435489A patent/CS274640B2/cs not_active IP Right Cessation
- 1989-07-17 DE DE68918191T patent/DE68918191C5/de not_active Expired - Fee Related
- 1989-07-17 CN CN89104960A patent/CN1022831C/zh not_active Expired - Fee Related
- 1989-07-17 NO NO892938A patent/NO172800C/no not_active IP Right Cessation
- 1989-07-17 PT PT91191A patent/PT91191B/pt not_active IP Right Cessation
- 1989-07-17 EP EP89201879A patent/EP0351918B1/en not_active Expired - Lifetime
- 1989-07-17 AT AT89201879T patent/ATE111459T1/de not_active IP Right Cessation
- 1989-07-17 ES ES89201879T patent/ES2058475T3/es not_active Expired - Lifetime
- 1989-07-18 HU HU893605A patent/HU202511B/hu not_active IP Right Cessation
- 1989-07-18 ZA ZA895458A patent/ZA895458B/xx unknown
- 1989-07-18 KR KR1019890010127A patent/KR970011286B1/ko not_active Expired - Fee Related
- 1989-07-18 IE IE232489A patent/IE64304B1/en not_active IP Right Cessation
- 1989-07-18 AU AU38240/89A patent/AU609319B2/en not_active Ceased
- 1989-07-18 DK DK198903541A patent/DK173115B1/da not_active IP Right Cessation
- 1989-07-18 JP JP1183818A patent/JPH0273078A/ja active Granted
- 1989-07-18 CA CA000606014A patent/CA1287639C/en not_active Expired - Lifetime
-
1993
- 1993-04-02 HR HRP930685AA patent/HRP930685B2/hr active IP Right Review Request
-
1994
- 1994-11-07 HU HU94P/P00040P patent/HU210533A9/hu unknown
- 1994-11-24 JP JP6289939A patent/JP2718422B2/ja not_active Expired - Fee Related
- 1994-12-01 HK HK136894A patent/HK136894A/en not_active IP Right Cessation
-
1995
- 1995-09-13 LV LVP-95-280A patent/LV11033B/en unknown
- 1995-10-20 CY CY181395A patent/CY1813A/xx unknown
-
1996
- 1996-11-05 JP JP8292997A patent/JPH09188672A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5442991B2 (ja) | ジアンヒドロヘキシトールジエステル組成物の調製方法 | |
| AR020494A1 (es) | Un procedimiento para la preparacion de esteres glicidilo de acidos monocarboxilicos ramificados | |
| ES2234323T3 (es) | Procedimiento para producir un precursor de simvastatina. | |
| WO2001028996A3 (en) | Pyrrolidine derivatives, their preparation and their use as inhibitors of neuraminidases | |
| BR0211227A (pt) | Composto, composição farmacêutica e seus usos | |
| EP0857717B1 (en) | Process for producing N-long-chain acyl acidic amino acids or salts thereof | |
| WO2010066674A3 (de) | Verfahren zur reinigung von polymethylolen | |
| Nitbani et al. | Synthesis and antibacterial activity 1-monolaurin | |
| US6649775B2 (en) | Process of lactonization in the preparation of statins | |
| DE10347863A1 (de) | Verfahren zur Herstellung von Benzoesäureestern | |
| AR020654A1 (es) | Proceso para la recuperacion por destilacion de monoetilenglicol de alta pureza obtenido por hidrolisis de oxido de etileno | |
| HRP20020730A2 (en) | A process for purifying lovastatin and simvastatin with reduced levels of dimeric impurities | |
| BR9909870A (pt) | Pirrolidinas como inibidores de neuraminidases | |
| EA199900675A2 (ru) | Полиморф моногидрата зополрестата | |
| Wimmer et al. | Preparation of carbamate derivatives of 2-(4-hydroxybenzyl)-1-cyclohexanone with a juvenoid activity | |
| Shigetomi et al. | Asymmetric total synthesis of 6-tuliposide B and its biological activities against tulip pathogenic fungi | |
| WO2001028979A3 (en) | Inhibitors of neuraminidases | |
| Hinterberger et al. | Synthesis of amides from Glycosmis species: methylthiopropenoic acid, methylsulfonylpropenoic acid, thiocarbamic acid S-methyl ester, and senecioic acid amides | |
| DE60216117T8 (de) | Verfahren zur herstellung von hexafluoraceton und dessen hydrat | |
| ES2136142T3 (es) | Cristales de un compuesto antimicrobiano. | |
| PA8469301A1 (es) | Procedimientos para la preparacion de acidos hidroxamicos. | |
| ES2170910T3 (es) | Procedimiento para la preparacion de oxido de rosas. | |
| RU2214407C2 (ru) | Усовершенствованный способ лактонизации при получении статинов | |
| SI21234A (sl) | Postopek laktonizacije za proizvodnjo izredno čistega simvastatina | |
| US5684168A (en) | β-phenylisoserine-(2R,3S), salts, preparation and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG3A | Patent granted, date of granting |
Effective date: 19940812 |
|
| MM4A | Annulment/lapse due to non-payment of fees, searched and examined patent |
Free format text: LAPSE DUE TO NON-PAYMENT OF FEES Effective date: 20080212 |